FolioLanternBeta
ATTOAttovia Therapeutics, Inc. · Insider ownership research

Attovia Therapeutics, Inc. insiders sold $2.3M in the past 12 months. How much of their stake is that?

Insiders sold $2.3M in the past 12 months.0% was sold under disclosed trading plans, 100% with no plan disclosed. The largest seller, Colin Walsh (Director), sold $2.3M.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why

Updated Oct 13, 2026 from SEC filings · covers Oct 14, 2025 to Oct 13, 2026
1
buyer among officers and directors (2 trades), past 12 months
0%
of sales were under disclosed trading plans, past 12 months
1 of 9
officers and directors sold shares, past 12 months
Latest filing: Filed Aug 28 for a sale on Aug 5. Colin Walsh sold 106K shares ($2.3M) with no plan disclosed. Filing
SEC ownership filings: 39 filed in the 12 months to Oct 13, 2026; 39 on record since Aug 4, 2026 · See the evidence

What stands out

Colin Walsh bought 585K shares for $10.3M, first on Aug 5, 2026. These are the first purchases by current officers or directors in the filings on record.Purchase, Aug 6, 2026
Colin Walsh sold $2.3M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Aug 5, 2026

A share of stake is shown for 0 of the 1 officer or director who sold. 9 are left out

i
Left out: Tao Fu, Petter Veiby, Zaneta Odrowaz, Angie You, Hubert Chen, John Smither, Mitchell Gold, Colin Walsh and Steven Chan (share of stake is being verified).
Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Colin Walsh
Director
Not confirmed
Share of stake not shown: share of stake is being verified. Why
$2.3MNo plan disclosed
Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

No plan disclosedOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMarAprMayJunJulAug 2026: $2.3M no plan disclosed$2.3MAugSepOct

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Aug 6, 2026Colin Walsh bought 500K shares ($8.5M).
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Colin Walsh
Director
500,000$17.00n/an/aAug 6, 2026Aug 28, 2026

Outside holders, reported separately

GOLDMAN SACHS GROUP INC sold $2.3M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Attovia Therapeutics, Inc. CEO selling stock?

No. Tao Fu reported no open-market sales in the past 12 months.

Why are Attovia Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 0% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 100% had no disclosed plan. A trading plan schedules sales in advance.

Are any Attovia Therapeutics, Inc. insiders buying?

Yes. 1 officer or director reported 2 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold1 officer or director: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan
Colin Walsh
Director
$2.3M
106K shares
Not confirmed
share of stake is being verified. Why
No plan disclosed

Outside holder, reported separately: Alamar HoldCo, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Attovia Therapeutics, Inc. (an outside shareholder, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Frazier Life Sciences XI, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Sanofi (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: GOLDMAN SACHS GROUP INC (a 10% owner, not part of management). Sold $2.3M (106K shares) from Aug 5, 2026 to Aug 5, 2026. Latest filing

Outside holder, reported separately: venBio Global Strategic Fund IV, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Vida Ventures GP III, L.L.C. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Redmile Group, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Deep Track Biotechnology Master Fund, Ltd. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 9 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 13, 2025SoldHeld Oct 13, 2026Still held
Tao Fu
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Tao Fu are complete.
President and CEO, Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Tao Fu

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tao Fu are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
23,437$1.58Aug 16, 2033$361K
409,709$3.53May 8, 2034$5.5M
370,290$4.92May 17, 2035$4.5M
538,300$17.00Aug 3, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Aug 6, 2026), not a market close.

Petter Veiby
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Petter Veiby are complete.
Chief Scientific Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Petter Veiby

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Petter Veiby are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
5,382$2.88Mar 5, 2034$76K
107,642$3.53May 8, 2034$1.4M
89,343$4.92May 17, 2035$1.1M
18,837$1.58Aug 16, 2033$290K
140,000$17.00Aug 3, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Aug 6, 2026), not a market close.

Zaneta Odrowaz
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Zaneta Odrowaz are complete.
Chief Business Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Zaneta Odrowaz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Zaneta Odrowaz are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
15,137$1.58Aug 16, 2033$233K
5,382$2.88Mar 5, 2034$76K
102,260$3.53May 8, 2034$1.4M
85,037$4.92May 17, 2035$1.0M
140,000$17.00Aug 3, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Aug 6, 2026), not a market close.

Angie You
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Angie You are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Angie You

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Angie You are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
19,913$4.92May 17, 2035$240K
27,000$17.00Aug 3, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Aug 6, 2026), not a market close.

Hubert Chen
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Hubert Chen are complete.
Chief Medical Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Hubert Chen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hubert Chen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
115,446$3.53May 8, 2034$1.6M
96,878$3.53May 8, 2034$1.3M
80,731$4.92May 17, 2035$975K
140,000$17.00Aug 3, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Aug 6, 2026), not a market close.

John Smither
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for John Smither are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for John Smither

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Smither are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
72,792$9.29Jul 1, 2036$561K

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Aug 6, 2026), not a market close.

Mitchell Gold
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mitchell Gold are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Mitchell Gold

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mitchell Gold are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
52,852$3.53Jun 28, 2034$712K
19,913$4.92May 17, 2035$240K
27,000$17.00Aug 3, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Aug 6, 2026), not a market close.

Colin Walsh
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Colin Walsh are complete.
Director
n/a−106Kn/an/a
Vesting, gifts, unvested awards and holding lines for Colin Walsh

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Colin Walsh are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
  • Some sales match sales reported by GOLDMAN SACHS GROUP INC exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.
Steven Chan
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Steven Chan are complete.
Chief Financial Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Steven Chan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Steven Chan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
215,285$3.53Nov 13, 2034$2.9M
80,731$4.92May 17, 2035$975K
140,000$17.00Aug 3, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Aug 6, 2026), not a market close.

Holdings and share of stake for Attovia Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$2.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $2.3M across 105,807 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

No plan disclosed · $2.3M

Sales with no 10b5-1 plan and no tax reference in the filing. $2.3M of it is Colin Walsh. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Colin Walsh, Aug 5, 2026

Purchases · 1 buyer (2 trades)

1 officer or director bought shares in this period, in 2 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 2 purchase trades.

SellerShares soldProceedsUnder a disclosed planShare of totalSales dates
Colin Walsh
Director
106K$2.3M0%100%Aug 5, 2026 to Aug 5, 2026

Sales by month

MonthSale proceedsDisclosed planTo cover taxesNo plan disclosed
Oct 2025$0$0$0$0
Nov 2025$0$0$0$0
Dec 2025$0$0$0$0
Jan 2026$0$0$0$0
Feb 2026$0$0$0$0
Mar 2026$0$0$0$0
Apr 2026$0$0$0$0
May 2026$0$0$0$0
Jun 2026$0$0$0$0
Jul 2026$0$0$0$0
Aug 2026$2.3M$0$0$2.3M
Sep 2026$0$0$0$0
Oct 2026$0$0$0$0
Known gaps and uncertainty9 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Attovia Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology39 filings on record, 39 filed in the 12-month period, and how we read them

All 39 Forms 3, 4 and 5 on record for Attovia Therapeutics, Inc. (SEC CIK 2058707), filed from Aug 4, 2026 to Oct 8, 2026; 39 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (2)No filing in 18 months; last reported balances, not in any total
NameLast filedLast reported balance
James TopperNo balance on record
Aaron RoystonNo balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.